88 related articles for article (PubMed ID: 7731702)
1. Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo.
Ishioka C; Englert C; Winge P; Yan YX; Engelstein M; Friend SH
Oncogene; 1995 Apr; 10(8):1485-92. PubMed ID: 7731702
[TBL] [Abstract][Full Text] [Related]
2. Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells.
Ishioka C; Shimodaira H; Englert C; Shimada A; Osada M; Jia LQ; Suzuki T; Gamo M; Kanamaru R
Biochem Biophys Res Commun; 1997 Mar; 232(1):54-60. PubMed ID: 9125151
[TBL] [Abstract][Full Text] [Related]
3. COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis.
Zhou X; Wang XW; Xu L; Hagiwara K; Nagashima M; Wolkowicz R; Zurer I; Rotter V; Harris CC
Cancer Res; 1999 Feb; 59(4):843-8. PubMed ID: 10029073
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
5. The basic carboxy-terminal domain of human p53 is dispensable for both transcriptional regulation and inhibition of tumor cell growth.
Pellegata NS; Cajot JF; Stanbridge EJ
Oncogene; 1995 Jul; 11(2):337-49. PubMed ID: 7624148
[TBL] [Abstract][Full Text] [Related]
6. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
7. p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles.
Rand A; Glenn KS; Alvares CP; White MB; Thibodeau SM; Karnes WE
Cancer Lett; 1996 Jan; 98(2):183-91. PubMed ID: 8556707
[TBL] [Abstract][Full Text] [Related]
8. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
[TBL] [Abstract][Full Text] [Related]
9. The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.
Kawaguchi T; Kato S; Otsuka K; Watanabe G; Kumabe T; Tominaga T; Yoshimoto T; Ishioka C
Oncogene; 2005 Oct; 24(46):6976-81. PubMed ID: 16007150
[TBL] [Abstract][Full Text] [Related]
10. [Establishment of mouse p53 yeast functional assay and evaluation of its detectability of p53 gene mutation].
Tsunematsu I
Hokkaido Igaku Zasshi; 1999 Jul; 74(4):301-14. PubMed ID: 10480037
[TBL] [Abstract][Full Text] [Related]
11. The polyproline region of p53 is required to activate apoptosis but not growth arrest.
Sakamuro D; Sabbatini P; White E; Prendergast GC
Oncogene; 1997 Aug; 15(8):887-98. PubMed ID: 9285684
[TBL] [Abstract][Full Text] [Related]
12. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
13. Signaling to p53: breaking the posttranslational modification code.
Appella E; Anderson CW
Pathol Biol (Paris); 2000 Apr; 48(3):227-45. PubMed ID: 10858956
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription.
Miller CW; Chumakov A; Said J; Chen DL; Aslo A; Koeffler HP
Oncogene; 1993 Jul; 8(7):1815-24. PubMed ID: 8510927
[TBL] [Abstract][Full Text] [Related]
15. The requirement of the carboxyl terminus of p53 for DNA binding and transcriptional activation depends on the specific p53 binding DNA element.
Zhang W; Guo XY; Deisseroth AB
Oncogene; 1994 Sep; 9(9):2513-21. PubMed ID: 8058314
[TBL] [Abstract][Full Text] [Related]
16. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters.
Kato S; Shimada A; Osada M; Ikawa S; Obinata M; Nakagawara A; Kanamaru R; Ishioka C
Cancer Res; 1999 Dec; 59(23):5908-11. PubMed ID: 10606233
[TBL] [Abstract][Full Text] [Related]
17. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants.
Greenblatt MS; Beaudet JG; Gump JR; Godin KS; Trombley L; Koh J; Bond JP
Oncogene; 2003 Feb; 22(8):1150-63. PubMed ID: 12606942
[TBL] [Abstract][Full Text] [Related]
18. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
[TBL] [Abstract][Full Text] [Related]
19. The DNA-binding and transcription-activation abilities of p53 are necessary but not sufficient for its antiproliferation function.
Zhang W; Randhawa GS; Guo XY; Deisseroth AB
Cell Growth Differ; 1994 Jul; 5(7):705-10. PubMed ID: 7947385
[TBL] [Abstract][Full Text] [Related]
20. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
